GBS Inc. Stock News

GBS Inc (GBS) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently down 80.3% year-to-date, down 86.8% over the past 12 months, and down 86.8% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.67 and as low as $1.26 this week.Shares closed 87.3% below its 52-week high and 27.8% above its 52-week low.Trading volume this week was 37.7% lower than the 10-day average and 88.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 175.4% The company's stock price performance over the past 12 months lags the peer average by 189.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at poin

In last trading session, GBS Inc. (NASDAQ:GBS) saw 0.39 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $1.80 trading at -$0.12 or -6.25% at ring of the bell on the day assigns it a market valuation of $25.72M. That closing price of GBS’s stock is at … GBS Inc. (NASDAQ:GBS) Lost -4.26% In A Week: What’s Driving The Stock? Read More »

GBS Inc. (NASDAQ:GBS) has seen 1.26 million shares traded in the recent trading session. The company, currently valued at $23.15M, closed the recent trade at $1.95 per share which meant it gained $0.33 on the day or 20.36% during that session. The GBS stock price is -630.26% off its 52-week high price of $14.24 and 20.36% Gain Drives GBS Inc. (GBS) Into Becoming A Interest-Loosing Stock For Investors Read More »

The stock price of GBS Inc (NASDAQ: GBS) increased by over 19% during intraday trading. This is why it happened.

Shares of GBS stock are trading higher after a clinical study at Harvard University yielded positive results for the company's antibody test. The post GBS Stock: The Covid Antibody Test News Shooting

GBS Inc (NASDAQ:GBS) will prepare for clinical trials of its rapid SARS-CoV-2 (COVID-19) Antibody test following the recent successful completion of a clinical validation study. As previously refer

GBS Inc. (NYSE:GBS) major shareholder Science Biosensor Diagnos Life sold 300,000 shares of the stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $2.02, for a total value of $606,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible []

GBS Inc. (GBS) CEO Steven Boyages on Q1 2022 Results - Earnings Call Transcript

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensee

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at

H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th

The stock price of GBS Inc (NASDAQ: GBS) increased by over 40% pre-market. These are some details you should know.

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets.

GBS Inc. (GBS) CEO Harry Simeonidis on Q4 2021 Results - Earnings Call Transcript